Experienced in Autosomal Recessive Hypotrichosis

Keisuke Tomii

Drs. Nagata And Tomii Are Affiliated With Department Of Respiratory Medicine, 
Kobe, JP 
Experienced in Autosomal Recessive Hypotrichosis
Drs. Nagata And Tomii Are Affiliated With Department Of Respiratory Medicine, 
Kobe, JP 
OverviewLocationsClinical Research

Overview

Keisuke Tomii practices in Kobe, Japan. Mr. Tomii is rated as an Experienced expert by MediFind in the treatment of Autosomal Recessive Hypotrichosis. His top areas of expertise are Pneumonia, Interstitial Lung Disease, Acute Interstitial Pneumonia, and Pulmonary Alveolar Proteinosis.

His clinical research consists of co-authoring 226 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Drs. Nagata And Tomii Are Affiliated With Department Of Respiratory Medicine, Kobe, Japan
Other Locations
Hongo, 1130033, Japan
Sayama, Japan
Osaka, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Japanese Idiopathic Interstitial Pneumonias Registry
Japanese Idiopathic Interstitial Pneumonias Registry
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2024
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2
View 3 Less Clinical Trials

226 Total Publications

PaO2/FIO2-Based Stratification Discriminates Treatment Failure in Nonintubated Subjects With ARDS.
PaO2/FIO2-Based Stratification Discriminates Treatment Failure in Nonintubated Subjects With ARDS.
Journal: Respiratory care
Published: September 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tomii's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 41 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile